Other Molecules in Pediatric Rheumatology (T-Cell Co-Stimulation Blockade, Interleukin-17, Interleukin-23 and Interferon-Gamma Targeted Therapies)

Şeyma TÜRKMENa , Betül SÖZERİa

aUniversity of Health Sciences Ümraniye Training and Research Hospital, Department of Pediatric Rheumatology, İstanbul, Türkiye

ABSTRACT
In pediatric rheumatology, traditional treatment modalities for autoimmune and inflammatory disorders affecting children and adolescents often include non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), and biologic agents. However, recent years have witnessed significant advances, especially with the development of targeted treatments that modulate the immune system. Especially, there has been a growing interest in T-cell co-stimulation blockade, interleukin-17 (IL-17), interleukin-23 (IL-23), and interferon-gamma (IFN-γ) targeted therapies due to their potential to offer improved disease control and quality of life for pediatric patients. This manuscript provides an overview of T-cell co-stimulation blockade, IL-17, IL-23, and IFN-γ targeted therapies in the context of pediatric rheumatology. We discuss the mechanisms of action, clinical efficacy, and safety profiles of these therapies, highlighting their potential in improving the quality of life for young patients with autoimmune and inflammatory rheumatic diseases.
Keywords: Child; rheumatology; CTLA-4; interleukin 17

Referanslar

  1. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133(5):775-87. [Crossref]  [PubMed]
  2. Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372(9636):383-91. [Crossref]  [PubMed]
  3. Foell J, McCausland M, Burch J, et al. CD137-mediated T cell co-stimulation terminates existing autoimmune disease in SLE-prone NZB/NZW F1 mice. Ann N Y Acad Sci. 2003;987:230-5. [Crossref]  [PubMed]
  4. Cather JC, Young CT, Young MS, Cather JC. Ixekizumab for the treatment of pediatric patients with moderate to severe plaque psoriasis. Expert Opin Biol Ther. 2021;21(8):983-90. [Crossref]  [PubMed]
  5. Brunner HI, Foeldvari I, Alexeeva E, et al. Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. Ann Rheum Dis. 2023;82(1):154-60. [Crossref]  [PubMed]  [PMC]
  6. Dayan JR, Dolinger M, Benkov K, et al. Real World Experience With Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease Center. J Pediatr Gastroenterol Nutr. 2019;69(1):61-7. [Crossref]  [PubMed]  [PMC]
  7. McInnes IB, Chakravarty SD, Apaolaza I, et al. Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2. RMD Open. 2019;5(2):e000990. [Crossref]  [PubMed]  [PMC]
  8. Sarangi S, Nahak SK, Padhi S, et al. Interferon-gamma (IFN-γ) intronic variant (rs2430561) is a risk factor for systemic lupus erythematosus: Observation from a meta-analysis. Lupus. 2023;32(2):284-94. [Crossref]  [PubMed]
  9. Kuriyama Y, Shimizu A, Kanai S, et al. Coordination of retrotransposons and type I interferon with distinct interferon pathways in dermatomyositis, systemic lupus erythematosus and autoimmune blistering disease. Sci Rep. 2021;11(1):23146. [Crossref]  [PubMed]  [PMC]
  10. Kuemmerle-Deschner JB, Benseler S. Abatacept in difficult-to-treat juvenile idiopathic arthritis. Biologics. 2008;2(4):865-74. [Crossref]  [PubMed]  [PMC]
  11. Jordan N, Lutalo PM, D'Cruz DP. Progress with the use of monoclonal antibodies for the treatment of systemic lupus erythematosus. Immunotherapy. 2015;7(3):255-70. Erratum in: Immunotherapy. 2015;7(6):707-8. [Crossref]  [PubMed]
  12. Moghadam-Kia S, Oddis CV, Aggarwal R. Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics. Clin Rev Allergy Immunol. 2017;52(1):81-7. [Crossref]  [PubMed]  [PMC]
  13. Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity. 2009;30(5):636-45. [Crossref]  [PubMed]
  14. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8(7):523-32. [Crossref]  [PubMed]  [PMC]
  15. Buchbinder EI, Desai A. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol. 2016;39(1):98-106. [Crossref]  [PubMed]  [PMC]
  16. Green L, Weinberg JM, Menter A, Soung J, Lain E, Jacobson A. Clinical and Molecular Effects of Interleukin-17 Pathway Blockade in Psoriasis. J Drugs Dermatol. 2020;19(2):138-43. [Crossref]  [PubMed]
  17. McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 Family of Cytokines in Health and Disease. Immunity. 2019;50(4):892-906. [Crossref]  [PubMed]  [PMC]
  18. Magnolo N, Kingo K, Laquer V, et al. Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study. Paediatr Drugs. 2022;24(4):377-87. [Crossref]  [PubMed]  [PMC]
  19. Maniscalco V, Maccora I, Girodo F, et al. Anti-IL17 treatment in childhood chronic rheumatic diseases. Expert Opin Biol Ther. 2023;23(5):429-41. [Crossref]  [PubMed]
  20. Huang YW, Tsai TF. Pharmacological Management of Pediatric Pustular Psoriasis. Paediatr Drugs. 2020;22(3):265-77. [Crossref]  [PubMed]
  21. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;314(5804):1461-3. [Crossref]  [PubMed]  [PMC]
  22. Emami S, Ziaee V, Rezaei A, et al. IL23R gene polymorphism with juvenile idiopathic arthritis and its association with serum IL-17A. Int J Rheum Dis. 2016;19(11):1189-96. [Crossref]  [PubMed]
  23. Toussirot E. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases. Inflamm Allergy Drug Targets. 2012;11(2):159-68. [Crossref]  [PubMed]
  24. Leu JH, Shiff NJ, Clark M, et al. Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis and Subcutaneous Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Extrapolation of Data from Studies in Adults and Adjacent Pediatric Populations. Paediatr Drugs. 2022;24(6):699-714. [Crossref]  [PubMed]  [PMC]
  25. Daniele SG, Eldirany SA, Ho M, Bunick CG. Structural basis for differential p19 targeting by IL-23 biologics. bioRxiv [Preprint]. 2023:2023.03.09.531913. [Crossref]
  26. Kellen R, Silverberg NB, Lebwohl M. Efficacy and safety of ustekinumab in adolescents. Pediatric Health Med Ther. 2016;7:109-20. [Crossref]  [PubMed]  [PMC]
  27. Gordon KB, Papp KA, Langley RG, et al. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol. 2012;66(5):742-51. [Crossref]  [PubMed]
  28. Fenimore J, A Young H. Regulation of IFN-γ Expression. Adv Exp Med Biol. 2016;941:1-19. [Crossref]  [PubMed]
  29. Put K, Vandenhaute J, Avau A, et al. Inflammatory Gene Expression Profile and Defective Interferon-γ and Granzyme K in Natural Killer Cells From Systemic Juvenile Idiopathic Arthritis Patients. Arthritis Rheumatol. 2017;69(1):213-24. [Crossref]  [PubMed]
  30. Patwardhan A, Spencer CH. Biologics in refractory myositis: experience in juvenile vs. adult myositis; part II: emerging biologic and other therapies on the horizon. Pediatr Rheumatol Online J. 2019;17(1):56. [Crossref]  [PubMed]  [PMC]
  31. Miserocchi E, Giuffrè C, Cornalba M, Pontikaki I, Cimaz R. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis. Clin Rheumatol. 2020;39(3):847-51. [Crossref]  [PubMed]
  32. Gillard L, Pouchot J, Cohen-Aubart F, et al. JAK inhibitors in difficult-to-treat adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. Rheumatology (Oxford). 2023;62(4):1594-604. [Crossref]  [PubMed]
  33. De Benedetti F, Grom AA, Brogan PA, et al. Efficacy and safety of emapalumab in macrophage activation syndrome. Ann Rheum Dis. 2023;82(6):857-65. [Crossref]  [PubMed]  [PMC]